Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats migraine with or without aura. Sold as Nurtec Odt. Every FDA application for this active ingredient.
As of Nov 22, 2026, FDA lists 1 application for Rimegepant sulfate (sold as Nurtec Odt), first approved Feb 27, 2020, with 2 new uses approved and 0 published complete response letters.
Each condition ChEMBL records for this drug, with the furthest stage reached and the trials it cites; approved means approved for that use somewhere, not necessarily in the US
What state Medicaid programs paid pharmacies in 2025, before rebates, by product name; see every drug
Nurtec
$632.7M for 499,751 prescriptions, +18% on 2024
Where Medicare prescribes it
426,510 Part D claims in 2024; each state's share of its claims against the national share; see Part D by state
Most, against the national rate
Colorado 1.6×, New York 1.5×, Kentucky 1.5×
Least
Puerto Rico 0.3×, New Mexico 0.7×, North Dakota 0.7×
How its trials ended
29 ClinicalTrials.gov studies testing it, classified by TrialPanorama, partly automatically, so some labels are wrong
Of the 11 whose ending is known, 73% met their primary endpoint, 0% missed it and 27% stopped early.
Ongoing1448%OngoingCount14Share48%
Met its primary endpoint828%Met its primary endpointCount8Share28%
Completed, result not reported414%Completed, result not reportedCount4Share14%
Stopped: other or unclear27%Stopped: other or unclearCount2Share7%
Stopped: sponsor or business decision13%Stopped: sponsor or business decisionCount1Share3%
Adverse event reports (FAERS)
Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3, from FDA's quarterly files. A report does not show the drug caused the event.
First approved in Japan 67 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Nurtec OD, new ingredientA drug with a new active ingredient indicated for the acute treatment and prevention of migraine attacks. · Pfizer Japan Inc. · Sep 19, 2025
Approvals in Canada (Health Canada)
First approved in Canada 45 months after the US. New drug submissions since 1994, matched by ingredient; see all Canadian approvals
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered.Drugs@FDA